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rther.umAbstract Accelerated radiotherapy (AR) improves the poor prognosis associated with epi-
dermal growth factor receptor (EGFR) overexpression frequently seen in head and neck car-
cinomas. Combining AR with carbogen and nicotinamide (ARCON) counteracts enhanced
tumour cell proliferation- and hypoxia-related radioresistance. The purpose of this study
was to investigate if EGFR expression levels are associated with response to ARCON in
patients with carcinoma of the larynx.
Patients (N = 272) with advanced stage larynx carcinoma were randomised between AR alone
and ARCON. Parafﬁn-embedded biopsies from these patients were processed for immunohis-
tochemical staining of EGFR. EGFR fraction was quantitated by automated image analysis
and related to clinical outcome.
A large variation was observed in EGFR fraction between tumours with expression levels
ranging from 0 to 0.93 (median fraction 0.4). No difference in 5-year locoregional control
was found between low and high EGFR expressing tumours in the AR arm (69% versus
75%), which is in line with the established effect of AR in EGFR overexpressing tumours.
There was, however, a signiﬁcant association in the ARCON arm: patients with low EGFRlsevier Ltd. All rights reserved.
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M.M. Nijkamp et al. / European Journal of Cancer 49 (2013) 3202–3209 3203levels had a better 5-year locoregional control (88% versus 72% p = 0.02) and disease-speciﬁc
survival (92% versus 77% p = 0.01). ARCON improved locoregional control relative to AR
only in patients with low EGFR expression (hazard ratio (HR) 0.34 p = 0.009).
In conclusion, only in tumours with a low EGFR fraction, adding hypoxia modiﬁcation to AR
has an additive beneﬁcial effect on outcome. EGFR expression is a predictive biomarker for
the selection of patients that will or will not respond to ARCON.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The epidermal growth factor receptor (EGFR) is a
transmembrane receptor tyrosine kinase that plays a
major role in regulating tumour cell proliferation and
cell cycle progression.1,2 EGFR is highly expressed in
many solid cancers, including head and neck squamous
cell carcinomas (HNSCC)3 and is correlated with resis-
tance to radiotherapy and decreased patient survival.4
Ligand binding as well as ionising radiation can phos-
phorylate EGFR5 leading to the activation of down-
stream cascades, like the phosphatidylinositol 3-kinase
(PI3-K)/AKT and the mitogen-activated protein kinase
(MAPK) pathways.6 These signalling pathways are
responsible for enhanced proliferation, cell cycle pro-
gression and increased DNA-repair leading to treatment
failure.2,7,8
How well tumour cells respond to radiotherapy
depends on their proliferative response induced by
and during treatment, their ability to repair the radia-
tion-induced DNA-damage and the amount of
hypoxia within a tumour.9 EGFR is involved in the
regulation of intrinsic DNA-repair mechanisms and
tumour cell proliferation via downstream pathway
activation.10 Tumour cell hypoxia induces radioresis-
tance, directly as DNA-damage is maximised in the
presence of oxygen and indirectly by promoting
genetic instability.11,12 An autocrine route has been
described by which hypoxia induces the expression
of EGFR and its ligands13,14 and in addition, EGFR
can stabilise one of the key proteins in the hypoxia
response namely hypoxia-inducible factor 1a
(HIF-1a).11 Thus, EGFR is involved in all aspects
of radioresistance. These resistance mechanisms play
a role in HNSCC while EGFR is expressed at high
levels in the majority of these tumours. This makes
head and neck cancer the tumour archetype to further
investigate these interactions.
Various studies have shown that enhanced tumour
cell proliferation can be counteracted by accelerated
radiotherapy (AR),15–17 while tumour hypoxia can be
reduced using hypoxia-modifying treatment modali-
ties.18 A strategy that combines both AR and hypoxia
modiﬁcation is accelerated radiotherapy with carbogen
(98% O2; 2% CO2) and nicotinamide (ARCON).
19
Results from clinical trials with ARCON show highlocoregional control rates, in particular for oropharynx
and larynx tumours.20,21
Both irradiation22 and hypoxia13 can enhance the
phosphorylation of EGFR thereby regulating intrinsic
DNA-repair mechanisms10 and cellular proliferation.
We therefore hypothesised that EGFR could modulate
the tumour response to accelerated radiotherapy with
hypoxia modiﬁcation. The purpose of our study is to
investigate the predictive value of EGFR expression
for ARCON in patients with advanced laryngeal carci-
noma using material from a recently completed trial
randomising between AR and ARCON.212. Materials and methods
2.1. Patients and treatment
Three-hundred-and-forty-ﬁve patients with advanced
laryngeal carcinoma were included in a randomised trial
comparing AR and ARCON between April 2001 and
February 2008 at seven centres for head and neck oncol-
ogy (six from the Netherlands and one from the United
Kingdom (UK)). The eligibility criteria were published
previously.21 Approval from the local Ethics Committee
of the Radboud University Nijmegen Medical Centre
was obtained and all patients gave written informed
consent. Pre-treatment paraﬃn-embedded biopsies were
retrieved for immunohistochemical staining.2.2. Immunohistochemistry
Sections from tumour biopsies were stained for EGFR
expression as described previously with minor modiﬁca-
tions.23 Brieﬂy, sections of 5 lm were cut, deparaﬃnised
and rehydrated through a graded ethanol series. Sections
were incubated with proteinase-K (DAKO, Glostrup,
Denmark) at 37 C. The primary antibody used was
mouse anti-EGFR (DAKOM7239, Glostrup, Denmark)
diluted 1:50 in PAD, primary antibody dilution (Gene-
Tex Inc., USA). The secondary antibody was a biotinyl-
ated F(ab)02-donkey anti-mouse immunoglobulin G
(IgG) (Jackson Immunoresearch Laboratories Inc., West
Grove, PA, United States of America (USA)), diluted
1:200 in phosphate buﬀered solution (PBS). Sections were
counterstained with haematoxylin.
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All patient tissue sections were scanned with a Leica
DM 6000 microscop (monochrome CCD camera
(Retiga SRV) with an RGB ﬁlter (Slider module,
QImaging, Burnaby, BC, Canada)) using IPlab imaging
software (Scananalytics Inc., Fairfax, VA, USA). EGFR
signal was scanned at 100 magniﬁcation. For every
scanning session a background image was recorded.
Extraction and separation of the individual colours
from the DAB (brown) and haematoxylin (blue) signals
was conducted using the RGB linear unmixing module
in the TRI2-software (Randall Division and Gray
Cancer Institute, London, UK). Based on a haematoxy-
lin/eosin stained consecutive section, the tumour area of
each section was delineated (necrotic areas and artefacts
excluded). The EGFR fraction was deﬁned as the
tumour area positive for EGFR relative to the total
tumour area. EGFR assays were performed blinded to
the clinical end-point.2.4. Statistical analysis
Statistical analyses were performed on a Macintosh
computer using Prism 4.0c (Hearne Scientiﬁc Software,
Dublin, Ireland) software package. Comparison of base-
line characteristics between patient groups was per-
formed using the v2-test for categorical variables, and
using the independent Students t-test for continuousTable 1
Patient and tumour characteristics of 272 laryngeal tumour patients.
All (%) Treatment (%)
ARCON (n = 138) AR (n =
Age 60.6 60.8 60.1
Median (range) (38–88) (42–84) (38–88)
Gender
Male 219 (81) 116 (84) 103 (77
Female 53 (19) 22 (16) 31 (23)
Primary site
Glottic 115 (42) 60 (43) 55 (41)
Supraglottic 157 (58) 78 (57) 79 (59)
T-classiﬁcation
T2 99 (36) 46 (33) 53 (39)
T3 133 (49) 73 (53) 60 (45)
T4 40 (15) 19 (14) 21 (16)
N-classiﬁcation
N0 178 (65) 91 (66) 87 (65)
N+ 94 (35) 47 (34) 47 (35)
Histopathological diﬀerentiation grade
Well 17 (6) 9 (7) 8 (6)
Moderate 153 (56) 78 (56) 75 (56)
Poor 47 (17) 29 (21) 18 (13)
n.k. 55 (20) 22 (16) 33 (24)
n.k., not known; EGFR, epidermal growth factor receptor; AR, accelerate
nicotinamide. Italic values signiﬁes p-value 6 0.05.variables. Correlations between the EGFR fraction
and ordinal tumour characteristics (T-classiﬁcation,
N-classiﬁcation and histopathological grade) were
assessed using the Spearman and the Kruskal–Wallis
tests. To determine correlations between EGFR expres-
sion level and survival (locoregional control (LCR) and
disease-speciﬁc survival (DSS)), Kaplan–Meier graphs
with log-rank testing were used after dichotomising the
patients into two groups based on low and high EGFR
fractions. p 6 0.05 was considered indicative of statisti-
cal signiﬁcance. Multivariate analysis was performed
using Cox proportional hazards analysis. Data are pre-
sented as hazard ratios (HRs) with 95% conﬁdence
intervals (CIs).3. Results
3.1. Patients and treatment
A total of 345 patients were randomised. From these,
73 patients were excluded from the current analysis, 39
because biopsy material could not be retrieved, 24 biop-
sies contained no or very little invasive carcinoma and
10 because of poor quality due to mechanical damage
during biopsy procedure or poor staining quality. Thus,
272 histological conﬁrmed squamous cell carcinomas of
the larynx were available for analysis. The minimal
duration of follow-up for all patients was 2 years with
a median of 52 months for surviving patients. PatientEGFR expression
134) p EGFR low EGFR high p
0.65 60.8 62.8 0.09
(39–83) (38–88)
) 0.13 112 (78) 107 (84) 0.23
32 (22) 21 (16)
0.68 58 (40) 57 (45)
86 (60) 71 (55) 0.48
50 (35) 49 (38)
0.40 76 (53) 57 (45) 0.33
18 (12) 22 (17)
0.79 104 (73) 74 (58) 0.01
40 (27) 54 (42)
8 (5) 9 (7)
79 (55) 74 (58)
0.18 26 (18) 21 (16) 0.71
31 (22) 24 (19)
d radiotherapy; ARCON, accelerated radiotherapy with carbogen and
M.M. Nijkamp et al. / European Journal of Cancer 49 (2013) 3202–3209 3205and tumour characteristics were not signiﬁcantly diﬀer-
ent between the AR and ARCON groups (Table 1).
Treatment schedules and patient outcome have been
published previously.213.2. EGFR expression and correlation with tumour
characteristics
Most tumours showed membranous EGFR expres-
sion (median fraction 0.4), but there was a wide range
(0.00–0.93) (Figs. 1 and 2). Based on the bimodal distri-Fig. 1. Range of the epidermal growth factor receptor (EGFR)
expression in laryngeal carcinoma (A) no expression; (B) intermediate
expression and (C) high expression at 400 magniﬁcation.
Fig. 2. Distribution of epidermal growth factor receptor (EGFR)
expression based on EGFR fraction of whole tissue section in 272
laryngeal tumours analysed in the accelerated radiotherapy with
carbogen and nicotinamide (ARCON) trial. Line represents cut-oﬀ.bution, patients were dichotomised at a fraction of 0.43,
resulting in a low EGFR fraction group (n = 144, 53%)
and a high EGFR fraction group (n = 128, 47%). There
was no correlation between EGFR levels and clinical
parameters except for a diﬀerence between EGFR high
and low groups with regard to N-classiﬁcation.
Tumours with high EGFR expression were more fre-
quently lymph node positive at the time of presentation
(Table 1).
3.3. Associations between EGFR expression and
treatment outcome
No diﬀerence in 5-year disease speciﬁc survival (DSS)
or locoregional control (LRC) was found between low
and high EGFR expressing tumours in the AR arm
(DSS 81% versus 78% and LRC 69% versus 75% respec-
tively) (Fig. 3A and C). In the ARCON arm, however,
EGFR fraction was a signiﬁcant prognostic factor for
DSS and LRC. Patients with low EGFR levels had a
better 5-year DSS (92% versus 77% p = 0.01) and
LRC (88% versus 72% p = 0.02) compared to patients
with high EGFR (Fig. 3B and D).
Table 2 shows the same data, now comparing AR
against ARCON in the subgroups of patients with low
and high EGFR fractions. ARCON improves 5-year
LRC relative to AR in patients with low EGFR fraction
(88% for ARCON versus 69% for AR p = 0.009; hazard
ratio (HR) 0.34) but there was no eﬀect of ARCON in
patients with high EGFR fraction. The same phenome-
non was observed for DSS, albeit that the diﬀerence was
borderline signiﬁcant (p = 0.08).
The multivariate analysis (Table 3) conﬁrmed EGFR
fraction as an independent predictive factor for DSS and
LRC in the patients treated with ARCON. After correc-
tion for T-, N-classiﬁcation and histopathological grade,
EGFR expression remained associated with LRC and
DSS in the ARCON treatment arm (HR 2.43 CI 1.01–
5.87 p = 0.048 and HR 3.00 CI 0.99–9.16 p = 0.05
respectively).
Fig. 3. Kaplan–Meier estimates of (A) disease-speciﬁc survival in accelerated radiotherapy (AR) arm versus (B) in AR with carbogen and
nicotinamide (ARCON) arm and (C) locoregional control in AR arm versus (D) in ARCON arm. Stratiﬁcation is by the cut-oﬀ value of epidermal
growth factor receptor (EGFR) fraction. Comparison by log-rank test.
Table 2
Five-years loco-regional control and disease-speciﬁc survival (%) and
hazard ratio of patients treated with ARCON versus AR by EGFR
expression fraction.
Outcome end-points AR ARCON p HR (95% CI)
Disease-
speciﬁc
survival
Low EGFR 82 91 0.08 0.38 (0.12–1.12)
High EGFR 77 78 0.54 1.23 (0.58–2.86)
Loco-regional
control
Low EGFR 69 88 0.009 0.34 (0.14–0.79)
High EGFR 75 71 0.85 1.07 (0.53–2.15)
HR, hazard ratio; CI, conﬁdence interval; AR, accelerated radiother-
apy; ARCON, accelerated radiotherapy with carbogen and
nicotinamide; EGFR, epidermal growth factor receptor. Bold values
signiﬁes p-value 6 0.05.
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ARCON, a new treatment option for larynx carci-
noma, combines AR with hypoxic modiﬁers to counter-
act enhanced tumour cell repopulation and reduce
intratumoural hypoxia.19 Selection of patients for new
treatments is traditionally based on standard clinical
and histopathological tumour characteristics. Predictive
assays, based on molecular tumour markers and the
oxygenation status of tumour cells, may provide better
tools to select patients for new treatment approaches.
EGFR is involved in all mechanisms of radioresistance
and we therefore hypothesised that EGFR could be a
powerful biomarker to predict tumour response to biol-
ogy-based radiotherapy modiﬁcations. In the current
study, we demonstrated that tumours with low EGFR
expression respond better to ARCON compared to
AR. EGFR expressing tumours were more likely to be
node positive. However, as ARCON is most eﬀective
for regional control,21 this putative bias would indicate
that the actual eﬀect may be even more pronounced.In tumours with a high EGFR fraction, adding hypoxia
modiﬁcation to AR had no additive beneﬁcial eﬀect on
outcome.
Biopsies of patients with advanced laryngeal carci-
noma were examined for EGFR expression. Similarly
to other studies,4,24–26 we observed a wide variation in
the EGFR expression levels. Most of the previous stud-
ies found a correlation between high (above median)
EGFR expression and worse clinical outcome. One of
the larger series including 155 head and neck cancer
patients demonstrated that EGFR expression was a
strong and independent prognostic indicator for LRC
(HR 1.95 p = 0.002) and overall survival (HR 1.75
p = 0.006).4 In this study, all patients were treated with
conventionally fractionated radiotherapy.4 Two subse-
quent randomised trials consistently demonstrated that
diﬀerences in outcome between high and low EGFR
expressing tumours disappeared when accelerated radio-
therapy was employed.26,27 The latter improves tumour
control only in tumours with high EGFR-expression
levels,26–28 most likely through suppression of
EGFR-induced tumour cell proliferation.
In the current study, both for the patient’s cohorts
with high as well as low EGFR expressing tumours,
5-year LRC in the AR arm was around 70%, conﬁrming
the observations in the previously mentioned studies
that acceleration radiation can counteract EGFR-asso-
ciated radiation resistance.26–28 Also in the tumours with
high EGFR-expression treated with ARCON, a LRC
rate of about 70% was obtained. However, the LRC
for tumours with low EGFR levels treated with
ARCON was signiﬁcantly improved (88%, p = 0.02).
So, patients with low EGFR expressing tumours beneﬁt
from ARCON, whereas patients with high EGFR
expressing tumours do not. Multivariate analysis
Table 3
Multivariate analysis of clinical parameters and EGFR fraction.
Variables DSS AR DSS ARCON LRC AR LRC ARCON
p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI)
T-classiﬁcation (T2 versus T3 versus T4) 0.156 1.54 (0.85–2.79) 0.726 1.14 (0.55–2.39) 0.349 0.79 (0.49–1.29) 0.261 1.39 (0.78–2.51)
N-classiﬁcation (N0 versus N+) 0.019 1.33 (1.05–1.69) 0.010 1.43 (1.09–1.87) 0.198 1.15 (0.93–1.41) 0.742 0.95 (0.69–1.25)
Histopathological grade (poor versus
moderate versus well)
0.571 0.96 (0.81–1.12) 0.367 0.88 (0.66–1.17) 0.321 0.94 (0.84–1.06) 0.283 1.08 (0.34–1.25)
EGFR fraction (low versus high) 0.912 0.95 (0.40–2.26) 0.05 3.00 (0.99–9.16) 0.507 0.79 (0.39–1.58) 0.048 2.43 (1.01–5.87)
HR, hazard ratio; CI, conﬁdence interval; EGFR, epidermal growth factor receptor; AR, accelerated radiotherapy; ARCON, accelerated
radiotherapy with carbogen and nicotinamide; DSS, disease-speciﬁc survival; LCR, locoregional control. Bold values signiﬁes p-value 6 0.05.
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predictor of LRC and DSS in patients treated with
ARCON.
From studies performed with EGFR inhibitors it is
known that EGFR signalling is associated with the
hypoxia response. Blocking EGFR can reduce intra-
tumoural hypoxia possibly by normalisation of the
irregular dysfunctional tumour vasculature, thereby
improving perfusion and oxygen delivery.29–31 A major
pathway in the hypoxia response is the HIF-pathway.
HIF-1 is a heterodimer consisting of two subunits:
HIF-1a and HIF-1b. Under normoxic conditions,
HIF-1a is rapidly degraded, but under hypoxia it is sta-
bilised.32 Interestingly, EGFR itself can induce the HIF-
1 pathway in an oxygen-independent way by stabilising
HIF-1a, thereby activating the same target genes.33Fig. 4. Fluorescence image from three xenografted larynx carcinomas sh
vessels (blue) and (B, D and F) an adjacent section pimonidazole (green) in
vessels (blue). HIF-1a expression is present in pimonidazole positive (hypox
100 lm.Tumour cells with high pre-treatment EGFR expression
levels might be better able to rapidly activate down-
stream survival pathways, resulting in activation of the
HIF-pathway, thereby thwarting the hypoxia modifying
eﬀect of ARCON. Low EGFR expressing tumours pos-
sibly lack this capacity and thus might be more likely to
respond to ARCON. ARCON might reduce activation
of the HIF-1 pathway in hypoxic tumours but possibly
cannot counteract the EGFR-induced HIF-response in
normoxic tumour cells. Therefore, in high EGFR
expressing tumours, the defence mechanism through
the HIF-1 pathway can still be active despite hypoxia
modiﬁcation. Fig. 4 illustrates that in laryngeal tumours
there is expression of HIF-1a present in normoxic and
EGFR-positive tumour areas, supporting this EGFR-
dependent HIF-response. Due to technical limitationsowing (A, C and E) hypoxia-inducible factor 1a (HIF-1a) (red) with
combination with epidermal growth factor receptor (EGFR) (red) and
ic) and negative (normoxic) areas. 100 magniﬁcation. Bar represents
Table 4
Chi-square.
Epidermal growth factor
receptor (EGFR) low
EGFR
high
Pimo low 21 28
Pimo high 8 14
p = 0.402.
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quantitatively. No correlation was found between over-
all fractions of EGFR and pimonidazole (Table 4). In
the absence of hypoxia upregulation of HIF-1 may drive
cells towards glycolysis, known as the Warburg eﬀect,
providing a growth advantage for tumour cells and
resistance to ionising radiation.11 Hypoxia-independent
but EGFR-dependent upregulation of HIF-1a could
account for the resistance of EGFR expressing tumours
to hypoxia-modifying treatment. This hypothesis will be
further explored in animal experiments. EGFR inhibi-
tors also have an eﬀect on the reoxygenation of tumour
cells.34,35 Possibly, in tumours with high EGFR expres-
sion signalling must be inhibited prior to ARCON
treatment in order to beneﬁt.
5. Conclusion
Current knowledge provides strong evidence that
EGFR signalling plays an important role in the regula-
tion of tumour cell survival during and after radiation
treatment. EGFR evolved from a prognostic marker
for patient outcome after conventional fractionated
radiotherapy to a predictive biomarker for the eﬀect of
accelerated radiotherapy. In the current study we dem-
onstrate that EGFR expression is also predictive for
the response to hypoxic modiﬁcation but with a reverse
association. In patients with laryngeal carcinomas with
low EGFR levels outcome can be further improved with
ARCON, while there is no advantage of ARCON for
patients with high EGFR expressing tumours. In the
latter, the eﬀect of EGFR inhibition in combination
with hypoxia modiﬁcation needs to be explored.Conﬂict of interest statement
None declared.
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